CONFERENCE PROGRAM

12THTH ANNUALOTTAWA CONFERENCESTATE OF THE ART CLINICAL APPROACHES

TO SMOKING CESSATION

JANUARY 17-18,

202

0

OTTAWA, CANADA

HEAR FROM SMOKING CESSATION EXPERTS

NETWORK WITH OTHER HEALTH PROFESSIONALS

LEARN OF CURRENT AND EMERGING CONCEPTS

AT THE END OF THIS CONFERENCE, PARTICIPANTS WILL BE ABLE TO:

TABLE OF CONTENTSPAGE 1 |

PAGE 2 |

PAGE 3 |

PAGE 4 |

PAGE 9 |

PAGE 14 |

PAGE 15 |

PAGE 16 |

WELCOME MESSAGE

SHAW CENTRE FLOORPLAN

CONFERENCE PLANNING COMMITTEE AND ACCREDITATION

AGENDA

SPEAKER BIOGRAPHIES

POSTER PRESENTATIONS

RAPID FIRE ORAL PRESENTATIONS

DISCLOSURE OF CONFLICTS OF INTEREST

| OTTAWAMODEL | #OMSC2020

Deliver evidence-based, clinical approaches to the treatment of tobacco addiction.

Demonstrate skills in facilitating smoking

cessation in a variety of practice settings.

Engage with other health professionals in knowledge sharing

activities regarding effective smoking cessation practice.

FOLLOW US

On behalf of the University of Ottawa Heart Institute, we are delighted to welcome everyone to the 12th annual “Ottawa Conference: State of the Art Clinical Approaches to Smoking Cessation”.

Twelve years! What an incredible and surprising journey this has been. We are pleased to report the Ottawa Model for Smoking Cessation network continues to grow - we have now worked with over 500 healthcare sites across Canada to implement systematic approaches to smoking cessation. The 2020 Ottawa Conference is yet another opportunity for us to share knowledge and to highlight the latest resources and research findings related to North America’s leading cause of preventable disease, disability and death – tobacco addiction.

As always, it is a privilege to welcome each of you to Ottawa. Close to 350 of you - health professionals, researchers, students, policy makers and smoking cessation champions - have braved the snow and cold to be in attendance this year.

We are extremely appreciative of the support from the Ontario Ministry of Health and Long Term Care and thank Johnson & Johnson for providing an educational grant to support this event.

There are numerous dedicated people working behind the scenes to make this event happen. Thank you to the planning committee for their efforts in organizing the conference; to our distinguished presenters, your willingness to share your knowledge, experience, and perspectives is greatly appreciated; and, to our outstanding team - your hard work and positivity do not go unnoticed.

Finally, to all attendees, thank you for your involvement in smoking cessation, and your commitment to enhancing the health of our patients and communities. We are pleased that you have joined us to celebrate more than a decade’s worth of accomplishments in the field of clinical smoking cessation.

Enjoy the conference, enjoy Ottawa, and we look forward to seeing you again next year!

Sincerely,

WELCOME MESSAGE

Andrew Pipe, CM, MD, LLD (HON), DSc (HON) Conference Co-ChairDivision of Prevention & RehabilitationUniversity of Ottawa Heart Institute

Robert Reid, PhD, MBA Conference Co-Chair, Deputy Chief

Division of Prevention & Rehabilitation University of Ottawa Heart Institute

1

REGISTRATIONTABLE

WASHROOMS

EXHIBITORS

POSTERPRESENTATION

209210

211212

OTTAWA SALON

COLONEL BY DRIVE

ELEVATOR

RIDEAU CANAL

SHAW CENTRE FLOORPLAN55 COLONEL BY D R, OT TA WA , ON K1N 9 J 2

DALY AVENUE

BRIDGE TO WESTIN

2

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada for 16 hours. This program has been reviewed and approved by the University of Ottawa, Office of Continuing Professional Development.

This Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by the University of Ottawa’s Office of Continuing Professional Development for up to 16 Mainpro+ credits.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 CreditsTM. Information on the process to convert Royal College MOC credit to AMA credit can be found at: ama-assn.org/go/internationalcme

PLANNING COMMITTEE

Andrew Pipe, CM, MD, LLD (HON), DSc (HON) Conference Co-Chair | Division of Prevention & Rehabilitation | University of Ottawa Heart Institute

Robert Reid, PhD, MBA Conference Co-Chair, Deputy Chief | Division of Prevention & Rehabilitation | University of Ottawa Heart Institute

Dave Cecillon, CD, BSc Chem, BSc Pharm, Pharm D Pharmacy Clinical Manager and Cardiac Surgery Intensive Care Pharmacist | University of Ottawa Heart Institute

Mustafa Coja, BPHE, BA, CSEP-CEPProgram Manager, Implementation Services | Ottawa Model for Smoking Cessation | University of Ottawa Heart Institute

Jo-Anne Gagnier, BScNClinical Manager and Implementation Specialist | Ottawa Model for Smoking Cessation | University of Ottawa Heart Institute

Marta Klepaczek, RN, APN, BScN Program Manager | Quit Smoking Program | University of Ottawa Heart Institute

Caroline Lawrance, RD, BScFN, BSc Implementation Specialist | Ottawa Model for Smoking Cessation | University of Ottawa Heart Institute

Pascale Leclair-Roberts, BA, MPH Program Officer, Knowledge Translation | Ottawa Model for Smoking Cessation | University of Ottawa Heart Institute

Sarah Mackler, BPh, WWHP(c), MBA Candidate Program Manager, Support, Development and Knowledge Translation | Ottawa Model for Smoking Cessation | University of Ottawa Heart Institute

Kerri-Anne Mullen, PhD Director of Prevention, Wellness and Women’s Heart Health | University of Ottawa Heart Institute

Kate Walker, MScPT, PhD Candidate Evaluation and Program Development Lead | Ottawa Model for Smoking Cessation | University of Ottawa Heart Institute

ACCREDITATION

3

8:30 a.m. - 9:00 a.m. BREAKFAST & REGISTRATION Pamela Heise, UOHI

9:00 a.m. - 9:45 a.m. T1a. IMPLEMENTING THE OTTAWA MODEL FOR SMOKING CESSATION IN ANY SETTING*1. Explain the key features of the Ottawa Model*2. Describe the rationale for the program and the adaptability of implementation

in a variety of clinical settings and specialty areas

Caroline Lawrance & Priscilla Bélanger,

UOHI

9:45 a.m. - 10:30 a.m. T1b. THE OTTAWA MODEL FOR SMOKING CESSATION IN THE TORONTO WESTERN FAMILY HEALTH TEAM: A TAILORED APPROACH*1. Identify a number of ways to tailor the OMSC specifically for use in one’s clinic,

through bringing forth a team’s unique knowledge, experience, and expertise to design supplementary activities and processes to put patients first and explore their experiences further

*2. Develop interventions to improve program metrics (Ask, Advise, and Act) as well as enhance the overall patient experience with the OMSC program

*3. Apply a Quality Improvement approach to implementing new strategies aimed at engaging providers and patients in a meaningful way

Teri Arany,Benjamin Kaasa,

Jadie Lo &Soumia Meiyappan,

Toronto Western Family Health Team

10:30 a.m. - 10:45 a.m. COFFEE BREAK

10:45 a.m. - 12:00 p.m. T1c. OVERCOMING IMPLEMENTATION SYSTEM CHALLENGES!Identify different scenarios and discuss how to implement a solution

• What is the problem we are trying to solve? (Overview)• What are the potential options? (Objectives)• How will you action/implement? (Solution)

Facilitated by:Lori Scholtz &

Sarah Mackler, UOHI

12:00 p.m. - 1:00 p.m. LUNCH

1:00 p.m. - 2:00 p.m. T2a. BEHIND THE LENS: EXPLORING THE EVIDENCE AND FINDING THE NARRATIVE IN THE JOURNEY TO REDUCING TOBACCO USE AND BECOMING SMOKE FREE FOR INDIVIDUALS LIVING WITH MENTAL ILLNESS. *1. Understand why smoking cessation is a such a critical issue for this client group,

the challenges to success, and the need for off label use and long term NRT*2. Understand how members of the Tobacco Freedom group used photography,

group dialogue, and mutual supports on their tumultuous journey to reduce/quit tobacco and cannabis

Panel of people with lived experience of

mental illness

Facilitated by: Joanne Haddad & Donna Pettey,

CMHA-Ottawa

2:00 p.m. - 2:15 p.m. COFFEE BREAK

2:15 p.m. - 3:15 p.m. T2b. HEAR MY STORY!  A LIVING ROOM CHATActivities:*1. Converse with an Expert Panel of people with lived experience of mental

illness and problematic substance use who will identify the array of skills and interventions practitioners in tobacco reduction need to have in order to support people in their tobacco cessation journey

*2. Identify important questions for practitioners to consider while exploring barriers to quitting, e.g. mental health, addiction (including cannabis use), physical health, comorbidities and other determinants of health

Panel of people with lived experience of

mental illness

Facilitated by: Joanne Haddad & Donna Pettey,

CMHA-Ottawa

3:15 p.m. END OF DAY

THURSDAY, JANUARY 16, 2020*Learning Objectives: By the end of the session, participants will be able to:

4

7:30 a.m. - 8:30 a.m. REGISTRATION AND CONTINENTAL BREAKFAST

8:30 a.m. OPENING CEREMONY Elder Monique Manatch

8:35 a.m. - 8:40 a.m. INTRODUCTORY COMMENTS Sarah Mackler, UOHI

8:40 a.m. - 9:00 a.m. CLINICAL SMOKING CESSATION IN 2020: CONTEMPORARY ISSUES AND CONTEMPORARY PRACTICE

*Interpret the philosophies and latest research underlying clinical smoking cessation interventions in the healthcare setting.

Dr. Andrew Pipe & Dr. Robert Reid,

UOHI

9:00 a.m. - 10:00 a.m. KEYNOTE PRESENTATIONE-CIGARETTES: BACK TO THE FUTURE*1. Understand what is an e-cigarette and how it works*2. Understand the effects on: cardiovascular and pulmonary systems and emerging

evidence on cancer; on cigarette smoking behavior; and on youth *3. Review policy options for controlling e-cigarettes

Dr. Stanton Glantz, University of

California, San Francisco

10:00 a.m. - 10:20 a.m. BREAK

10:20 a.m. - 12:00 p.m. BREAKOUT SESSIONS (10:20 – 11:05 and repeated again from 11:15 – 12:00)F1. THE MASTER CLASS: A CONVERSATION WITH DR. ANDREW PIPE AND DR. STANTON GLANTZ*Outline landmark approaches to smoking cessation through an open and informed conversation with an international renowned tobacco cessation expert.

Dr. Stanton Glantz, University of

California, San Francisco

F2. HOW TO ADDRESS COUNSELLING CHALLENGES WITHIN YOUR SETTING *1. Identify challenging client barriers to tobacco cessation*2. Apply strategies to address these barriers through clinical case examples

Rosa Dragonetti, CAMH

F3. WHAT’S COOKING IN THE OTTAWA MODEL TEST KITCHEN? *Summarize the latest evidence from the University of Ottawa Heart Institute's Smoking Cessation Research department, how it’s being applied, and where the field is headed next.

Dr. Kerri-Anne Mullen,UOHI

F4. INSIGHTS IN TOBACCO TRENDS, E-CIGARETTES, AND CANNABIS USE IN CANADA *1. Understand current patterns and trends in tobacco use and cessation in Canada*2. Consider current trends in e-cigarette and cannabis use in Canada, and how they

may relate to tobacco use and cessation

Jessica Reid, University of Waterloo

12:00 p.m. - 1:00 p.m. LUNCH

1:00 p.m. - 2:00 p.m. WHAT DO SMOKERS WANT?*1. Determine the challenges smokers face when considering cessation*2. Explore novel opportunities for healthcare professionals to assist

Panel of Current andFormer Smokers

2:00 p.m. - 2:30 p.m. IT’S NEVER TOO LATE TO QUIT! IMPLEMENTING CESSATION WITHIN CANCER CENTERS*1. Understand why it is important to help cancer patients to stop smoking at any

time in their cancer journey*2. Understand how to address the “myths” that are often a barrier to implementing

an effective smoking cessation program for cancer patients

Dr. William Evans, McMaster University

FRIDAY, JANUARY 17, 2020*Learning Objectives: By the end of the session, participants will be able to:

5

2:30 p.m. - 2:50 p.m. BREAK

2:50 p.m. - 3:20 p.m. HOW GENETICS CAN INFLUENCE SMOKING AND CESSATION*1. Understand how the genetic variation in nicotine metabolism alters smoking

behaviours*2. Understand how a genetics could be used to optimize smoking cessation

treatment choices

Dr. Rachel Tyndale, University of Toronto

3:20 p.m. - 4:20 p.m. CANNABIS: WHAT WE KNOW AND WHAT THE FUTURE HOLDS *Discuss the latest known research and identify the challenges in cannabis legalization, regulation, and control.

Panelist and Moderator: Dr. David Hammond,

University of Waterloo

Panelists:Dr. Andrew Pipe,

UOHI

Rebecca Jesseman, Canadian Centre on Substance Use and

Addiction

4:20 p.m. - 4:30 p.m. CLOSING REMARKS Dr. Robert Reid, UOHI

4:30 p.m. - 6:00 p.m. WINE AND CHEESE POSTER SESSION

FRIDAY, JANUARY 17, 2020*Learning Objectives: By the end of the session, participants will be able to:

56

| OTTAWAMODEL | #OMSC2020FOLLOW US

7:30 a.m. - 8:30 a.m. REGISTRATION AND CONTINENTAL BREAKFAST

8:30 a.m. - 8:45 a.m. INTRODUCTORY COMMENTS Jo-Anne Gagnier, UOHI

8:45 a.m. - 9:35 a.m. KEYNOTE PRESENTATIONISN’T IT TIME TO START TALKING ABOUT PHASING OUT CIGARETTE SALES? SUPPORTING SUCCESS IN SMOKING CESSATION BY CHANGING THE POLICY ENVIRONMENT*1. Identify the main objections to the idea of phasing out cigarette sales and how

these may be addressed *2. Describe how the evidence suggests phasing out sales of cigarettes would help

smokers quit *3. Discuss potential messaging strategies to build support for a goal of ending

cigarette sale

Dr. Ruth Malone, University of California

San Francisco

9:35 a.m. - 10:00 a.m. “HELPING JONATHAN QUIT”: A LONG AND WINDING ROAD*1. Describe the 3 year quit journey of a smoker with schizoaffective disorder in a

pharmacist-led smoking cessation program*2. Discuss the impact that a variety of challenges have had on his ability to quit *3. Discuss the evolution in attitude, priorities, skills, and scope of practice of the

pharmacist working with him

Dr. Leslie Phillips, Memorial University

10:20 a.m. - 12:00 p.m. BREAKOUT SESSIONS (10:20 – 11:05 and repeated again from 11:15 – 12:00)

S1. HOLY SMOKES! MY PHARMACIST CAN DO WHAT NOW?*1. Describe the pharmacist’s role in initiating therapy for smoking cessation *2. Discuss current initiatives targeting harmonization of pharmacist-led smoking

cessation services

Nardine Nakhla, University of Waterloo

S2. DIGITAL CESSATION TOOLS: MIXED METHODS RESEARCH ON ENGAGEMENT AND EFFECTIVENESS *Describe what we know, what we don’t know and what would we like to know about technologies and other innovations for addressing tobacco cessation.

Dr. Michael Amato, The Truth Initiative

S3. SMOKIN AND A TOKIN: CANNABIS AND TOBACCO CO-USE 101 *Describe the realities of tobacco users who co-use cannabis and the implications for helping co-users quit tobacco.

Kate Walker, UOHI

S4. WHAT’S COOKING IN THE CAMH TEST KITCHEN? *Summarize the most impactful and late breaking research findings related to the neurobiology and treatment of nicotine addiction.

Dr. Laurie Zawertailo, CAMH

12:00 p.m. - 1:00 p.m. LUNCH

1:00 p.m. - 1:35 p.m. RAPID FIRE ORAL PRESENTATIONS “5 MINS, 3 SLIDES!”*Summarize new experiences, insights and interesting research results in the field of smoking cessation as presented by our conference delegates.

Multiple Presenters

Moderated By: Mustafa Coja,

UOHI

SATURDAY, JANUARY 18, 2020*Learning Objectives: By the end of the session, participants will be able to:

7

1:35 p.m. - 2:00 p.m. BEYOND SELFIES AND LIKES: HOW TO UTILIZE SOCIAL MEDIA WITHIN YOUR PRACTICE*1. Contrast different social media platforms in the context of how they might both

enhance communication, increase understanding, foster collaborations as well as describe the pros and cons of each

*2. Select a personal use profile for social media – consumer, curator, advocate, and understand the differences between each

Dr. Yoni Freedhoff, Bariatric Medical

Institute

2:00 p.m. - 2:15 p.m. BREAK

2:15 p.m. - 2:45 p.m. EVIDENCE AND ISSUES ABOUT THE PRACTICAL USE OF ELECTRONIC CIGARETTES IN CESSATION PRACTICE*Discuss the latest evidence and challenges of e-cigarettes for smoking cessation.

Dr. Hayden McRobbie, Queen Mary University

of London

2:45 p.m. - 3:00 p.m. AWARDS CEREMONY AND CLOSING REMARKS Dr. Andrew Pipe & Dr. Robert Reid, UOHI

3:00 p.m. - 3:15 p.m. Closing Ceremony and End of Event Elder Monique Manatch

SATURDAY, JANUARY 18, 2020*Learning Objectives: By the end of the session, participants will be able to:

8

| OTTAWAMODEL | #OMSC2020FOLLOW US

SPEAKER BIOGRAPHIES

9

MICHAEL S. AMATO, PhD | Dr. Michael Amato is Methodologist for the Innovations center at Truth Initiative, and a research investigator with the Truth Initiative Schroeder Institute. He is also is also Assistant Professor of Medicine (Adjunct) at the Mayo Clinic College of Medicine and Science.

Dr. Amato’s background is in behavior change communication, tobacco control policy, and quantitative methods. His research uses rigorous quantitative methods to investigate how online smoking cessation programs can best help smokers quit, with particular focus on the relationship of program engagement with successful quitting. He leads the data team that supports and evaluates Truth Initiative’s digital cessation programs including The EX Program, BecomeAnEX and This Is Quitting.

ROSA DRAGONETTI, MSc, RP, CTE | Rosa Dragonetti is currently the Project Director of Addictions Research and Education at CAMH in the Nicotine Dependence Service. Rosa plays a key role in developing a strategy for education research and programming initiatives including the TEACH project. The TEACH project delivers

a Certificate program in Tobacco Cessation Counselling to healthcare professionals. While TEACH offers training in person, under Rosa’s leadership, the team has been developing an extensive online program offering several courses to support the certificate program. Rosa also supports training for the STOP Program, PREGNETS, Canadaptt and various other tobacco-related projects. She has delivered many workshops across Canada and internationally. Rosa has co-authored several journal articles and book chapters.

W.K (BILL) EVANS, MD, FRCPC | Dr. Bill Evans is a medical oncologist with a career-long interest in lung cancer. He chaired the Ontario provincial Lung Disease Site Group that developed over 20 practice guidelines during his tenure as Chair and he co-led the Ontario Lung Disease Pathway initiative that resulted in the

development of diagnostic and treatment pathways for lung cancer, lung diagnostic assessment programs in all regions of the province and a series of other priority actions that included a focus on smoking cessation in regional cancer centers. He is Cancer Care Ontario’s Clinical Advisor on Smoking Cessation and the current Chair of CCO’s Smoking Cessation Advisory Committee.

At the end of June 2013, he retired from Hamilton Health Sciences and is now Professor Emeritus in the Department of Oncology, McMaster University. He is a current member of the Board of the Hamilton Community Foundation and the Hamilton Cancer Assistance Program, which provides a variety of free services to cancer patients in the Greater Hamilton area. He also hosts a monthly radio show on CHML 900 AM called the Cancer Assistance Show with Dr. Bill Evans. Dr. Evans is also a member of the IASLC Tobacco Control and Smoking Cessation committee and the ESMO Cancer Medicines and Public Policy Committees.

YONI FREEDHOFF, MD | Yoni Freedhoff is an Associate Professor of Family Medicine at the University of Ottawa, the medical director of the Bariatric Medical Institute and Constant Health, and an outspoken public health advocate. His book, The Diet Fix, was a number one national bestseller, and his blog Weighty Matters,

has enjoyed over 21,000,000 visits. He also suffers with some unnamed pathology that has him spending far too much time on Twitter.

TERI ARANY, BScN, MHA(C) | Teri Arany is the Executive Director of the Toronto Western Family Health Team (TW FHT), University Health Network. She has been in the healthcare sector for 20 years, in acute, ambulatory and primary care environments. She is responsible for advancing the TW FHT’s strategic plans, goals and

partnerships, and for the overall management leadership for service delivery and change initiatives.

SPEAKER BIOGRAPHIES

10

STANTON GLANTZ, PhD | Dr. Glantz, the Truth Initiative Distinguished Professor of Tobacco Control, conducts research on a wide range of topics ranging from the health effects of secondhand smoke (with particular emphasis on the cardiovascular system) to the efficacy of different tobacco control policies. As the tobacco

landscape has changed, Dr. Glantz’ work has expanded to include e-cigarettes and marijuana, both of which are expanding the tobacco epidemic. He is a globally recognized expert on e-cigarettes and is applying his understanding of the tobacco industry to the emerging marijuana industry as well as the sugar industry.

Dr. Glantz is Director of the UCSF Center for Tobacco Control Research and Education, Co-Leader of the Helen Diller Familiy Comprehensive Cancer Center Tobacco Program and a member of the Cardiovascular Research Institute and Philip R. Lee Instiute for Healh Policy Studies. He served for 10 years as an Associate Editor of the Journal of the American College of Cardiology and is a member of the California State Scientific Review Panel on Toxic Air Contaminants. He was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2005.

DAVID HAMMOND, PhD | David Hammond is a Professor in the School of Public Health & Health Systems at the University of Waterloo. Professor Hammond’s research focuses on tobacco control, cannabis use and nutrition policies. Professor Hammond works closely with governments around the world and has served as

an Advisor for the World Health Organization. Professor Hammond also serves as an Expert Witness in court cases, primarily on behalf of governments defending health regulations from legal challenges by the food and tobacco industries. Professor Hammond’s research has been recognized by awards from CIHR, the Canadian Cancer Society, the Canadian Medical Association, the Royal Statistical Society of Canada, and the World Health Organization.

REBECCA JESSEMAN | Rebecca Jesseman is a respected and recognized subject-matter expert on drug policy. She believes that policy change should align with evidence, and respond to evolving health and social needs. She provides trusted counsel and expert commentary and presentations at the national and

international levels. She has received invitations to share her expertise with the Canadian parliament, numerous provincial governments, law enforcement, educators and service providers.

Rebecca is CCSA’s longest-tenured expert, originally joining the Centre in August 2006. In addition to her role at CCSA, Rebecca currently serves as chair of the Ottawa-Carleton Detention Centre Community Advisory Board. Previously she served as president on the Board of Directors for the House of Hope.

Rebecca draws on her previous experience with Public Safety Canada and Health Canada, and as a part-time professor of criminology at the University of Ottawa. She also holds a Master’s degree in criminology from the University of Ottawa.

BENJAMIN KAASA, MD, MScCH, CCFP | Benjamin Kaasa is a family physician at the Toronto Western Family Health Team (TWFHT) and a hospital medicine physician at the University Health Network.  He has collaborated on an interdisciplinary team to steward the TWFHT COPD strategy and more recently on the

design and implementation of the Ottawa Model for Smoking Cessation at the TWFHT.  He is an assistant professor in the Department of Family and Community Medicine at the University of Toronto and the program director for the PGY-3 enhanced skill year in Hospital Medicine.

JOANNE HADDAD, BSc, RN | Joanne Haddad is a registered nurse who has worked in a variety community mental health settings for over 35 years. She has worked at CMHA Ottawa since 2005 and is currently with the Concurrent Disorder team. Her main roles and functions includes providing smoking reduction supports to

people who receive services at CMHA Ottawa and some partner agencies. She is a certified Psychosocial Rehabilitation trainer. Her role as RN has evolved to include recovery oriented, strengths based clinical services, concurrent disorder/DBT group facilitators, promotion of peer support services.

SPEAKER BIOGRAPHIES

SOUMIA MEIYAPPAN, MSc, PMP | Soumia Meiyappan is a Project Leader in the Toronto Western Family Health Team (TW FHT), University Health Network. She plans, executes, and delivers projects that respond to the health needs of the local community. Projects include: leading the design and implementation

of the Ottawa Model for Smoking Cessation at the TWFHT, leading the unit to prepare for the latest organizational accreditation using standards built upon best practices, and managing the project of relocating the Family Medicine clinic from the Toronto Western Hospital to a new site.

11

JADIE LO, BScPhm, MHM, RPh | Jadie Lo is a Pharmacotherapy Specialist at Toronto Western Family Health Team (TWFHT). She has been working in the primary care setting for most of her career and is part of the Task Force for implementing and adapting the Ottawa Model for Smoking Cessation at TWFHT. She has a strong

interest in chronic disease management and prevention and completed her Master in Health Management with a focus on knowledge translation.

RUTH E. MALONE | Ruth E. Malone is Professor Emerita, Department of Social and Behavioral Sciences, University of California, San Francisco. Since 2009, she has been editor-in-chief of the leading tobacco policy journal, Tobacco Control, published by BMJ. She is internationally known for her research on the social,

political and policy dynamics of tobacco control, including the tobacco industry’s responses to public health and its influence on smoking among particular groups. Her work has been funded by the U.S. National Cancer Institute, National Institute on Drug Abuse and California Tobacco-Related Disease Research Program. She has consulted for the US Centers for Disease Control, US Department of Justice, and WHO. Her writing and research for the last decade have focused on articulating and advancing the tobacco endgame.

HAYDEN MCROBBIE, MB ChB (OTAGO), PhD (LONDON), FASLM | Professor Hayden McRobbie is a health behaviour change expert with a special interest in tobacco and obesity.Hayden graduated with his degree in medicine and surgery from the University of Otago in 1996. After working

in general medicine and surgery for three years he moved to the UK to take up a post in the Tobacco Dependence Research Unit (now the Health and Lifestyle Unit) at the Wolfson Institute of Preventive Medicine. Whilst working in the unit he completed his PhD (Medical Psychology), which focussed on tobacco withdrawal symptomatology.

Hayden is an experienced researcher with skills in undertaking large randomised controlled trials, cohort studies and surveys.  His main areas of research are in: (1) the treatment of tobacco dependence with a current focus on electronic cigarettes and digital strategies; and (2) behavioural interventions for weight management.

He is a Professor at the National Drug and Alcohol Research Centre, University of New South Wales, Australia, and a Consultant in Lifestyle Medicine at Lakes District Health Board, New Zealand. He is also Fellow of The Australasian Society for Lifestyle Medicine, and serves on the editorial boards of Addiction and Nicotine & Tobacco Research.In the last decade Hayden has played a key role in Tobacco Control in New Zealand and over the past 3 years has acted as the Clinical Champion in Child Obesity for the New Zealand Ministry of Health.

KERRI-ANNE MULLEN, PhD | Kerri-Anne has been with the University of Ottawa Heart Institute since 2006 where she and her team have worked with hundreds of healthcare organizations to implement and evaluate clinical approaches to the treatment of tobacco addiction. She received her BSc at the University of

Ottawa, her MSc at the University of Illinois, Urbana-Champaign, and her PhD in Population Health at the University of Ottawa. She is a Scientist with the Ottawa Heart Institute Research Corporation. Her work has been funded by the Ontario Ministry of Health and Long-Term Care, Health Canada, and the Canadian Institutes of Health Research. Kerri’s research interests include program implementation and the health services, economic, and health impacts of prevention interventions..

SPEAKER BIOGRAPHIES

LESLIE PHILLIPS, PHARM D | Dr. Phillips is a professor and mental health pharmacist with Memorial University’s School of Pharmacy and Faculty of Medicine: Discipline of Psychiatry. She has a Bachelor of Science in Pharmacy (Memorial University) and a Doctor of Pharmacy (UBC) degree, as well a postdoctoral

Residency in Psychopharmacy (UBC & Riverview Hospital).

She recently discovered her love of all things smoking cessation related! For the past 4 years, she has delivered a smoking cessation program through the School of Pharmacy’s Medication Therapy Services Clinic - a pharmacist-led clinic that provides a number of medication-related services to the public. She currently leads a research project which is an RCT looking at the efficacy of this program versus a shorter version designed for implementation in community pharmacies versus usual care. She teaches smoking cessation to pharmacy students and psychiatry residents and was heavily engaged with the adoption of the OMSC by Newfoundland’s Eastern Health Authority. She also serves on Newfoundland’s Alliance for the Control of Tobacco’s: Youth Tobacco and Vaping Reduction Working Group and is the NL representative on Pharmacists for a Smoke Free Canada.

NARDINE NAKHLA, PHARMD, RPH | Dr. Nakhla is a community pharmacist and academic with a keen interest in minor ailments and self-care. As a faculty member at the University of Waterloo School of Pharmacy, Dr. Nakhla has spent the past decade designing and delivering education on the assessment

of self-treating patients and the management of ambulatory conditions. She has authored four chapters for the Canadian Minor Ailments reference & regularly writes about non-prescription drugs & common ailments for the OTC Issues Column of the Pharmacy Practice + Business Journal.

12

DONNA PETTEY, PhD | Donna Pettey has worked for over 35 years in community mental health and is currently the Director of Operations-Integration, Research and Evaluation at the Canadian Mental Health Association Ottawa Branch. CMHA works with individuals with serious mental illness who are homeless or

vulnerably housed with a significant co-occurrence of substance misuse, including a tobacco use prevalence of over 70%. Donna is a registered social worker and has a PhD in Population Health.

ANDREW PIPE, C.M., M.D., LL.D. (HON), D.SC. (HON) FRCSPS(HON) | Dr. Andrew Pipe graduated from Queen’s University and was formerly Chief of the Division of Prevention and Rehabilitation at the University of Ottawa Heart Institute; he continues his academic activities within the Division. A Professor in the Faculty of Medicine at the University of Ottawa he is currently involved in clinical research assessing novel

initiatives to prevent cardiovascular disease, strategies designed to facilitate exercise adoption, and new approaches to smoking cessation. Dr. Pipe has addressed audiences in over 30 nations and is frequently consulted on issues related to tobacco use and smoking cessation.

The founding-Chair of Physicians for a Smoke-Free Canada, he has received honourary degrees from Queen’s University (LLD), Brock University (DSc) and the University of Guelph (DSc). In 2002 he was named to the Order of Canada. Dr. Pipe is currently the Chair of the Board of the Heart and Stroke Foundation of Canada.

ROBERT REID, PhD, MBA | Dr. Robert Reid is Deputy Chief of the Division of Prevention and Rehabilitation at the University of Ottawa Heart Institute, and a Professor in the Faculty of Medicine at the University of Ottawa. Dr. Reid is one of Canada’s leading health behavior change experts, particularly concerning

smoking cessation, physical activity promotion, dietary change and cardiovascular rehabilitation. He is a main inventor of the Ottawa Model for Smoking Cessation, a systematic approach to identifying and assisting smokers in clinical practice settings. His research is funded by the Canadian Institutes for Health Research, the Heart and Stroke Foundation of Canada, the Canadian Cancer Society Research Institute, the Ontario Ministry of Health, and the Public Health Agency of Canada.

SPEAKER BIOGRAPHIES

RACHEL TYNDALE, PhD | Rachel Tyndale PhD is head of Pharmacogenetics at the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, the Canada Research Chair in Pharmacogenomics. She is a Professor in the Departments of Pharmacology & Toxicology, and Psychiatry

at the University of Toronto. Dr. Tyndale focuses on sources of variation between individuals in drug response in the clinical area of addictions and mental health. Dr. Tyndale seeks to identify and understand risk factors, and underlying mechanisms, in substance dependence and to implement approaches to personalize treatment. Her laboratory program also has a major interest in understanding how interindividual variation in drug metabolizing enzymes within the brain alter drug and toxin effects. Dr. Tyndale sits on numerous scientific advisory boards, editorial boards, chaired NIH’s PharmacoGenomics Research Network (PGRN.org), and is a lead writer for the Surgeon General’s Report on Tobacco Cessation. Dr. Tyndale has supervised over 100 scientists, post-doctoral fellows and graduate students, published over 400 papers and book chapters, given over 250 invited presentations and received over 50 awards in clinical and basic pharmacology, neuroscience and genetics.

JESSICA REID | Jessica Reid is a Project Manager in the School of Public Health & Health Systems at the University of Waterloo. She is the lead author for the Tobacco Use in Canada report series, and has worked on projects under the International Tobacco Control Policy Evaluation Project (ITC) for the last decade, including

co-ordinating international studies on cigarette packaging and health warnings, and surveys of youth vaping and tobacco use.

KATE WALKER, MScPT, PhD CANDIDATE | Kate, a registered physiotherapist, is the Evaluation and Program Development Lead for the Ottawa Model for Smoking Cessation (OMSC) program at the University of Ottawa Heart Institute. Kate received her BSc and BPHE from Queen's University and her MScPT from McMaster

University. She is currently pursuing her PhD in Population Health at the University of Ottawa. Prior to joining the University of Ottawa Heart Institute, Kate worked as a researcher at McMaster University’s Evidence-Based Practice Centre and practiced physiotherapy in the community with a focus on chronic pain.

13

LAURIE ZAWERTAILO, PhD | Dr. Laurie Zawertailo is a Senior Scientist in the Addictions Research Program at the Centre for Addiction and Mental Health and an Associate Professor in the Department of Pharmacology and Toxicology at the University of Toronto Faculty of Medicine. She obtained her PhD in

Pharmacology at the University of Toronto in 2001 and completed a post-doctoral fellowship in Tobacco Use in Special Populations at CAMH where has been a scientist since 2005. Dr. Zawertailo’s research interests are in the areas of behavioural and neurobiological aspects of tobacco dependence and treatment. Since 2013 her program of research has included e-cigarettes and she has received over $1 million in funding for e-cigarette research in several domains and is about to undertake a neuroimaging study of young adult e-cigarette users. Dr. Zawertailo utilizes a variety of research techniques in order to further our understanding of tobacco dependence and e-cigarettes including neuroimaging, behavioural and cognitive tasks such as cue-induced craving, genetics, randomized clinical trials, and large population-based approaches to smoking cessation with over 50 publications in this area of research. She is the co-principal investigator of the STOP (Smoking Treatment in Ontario Patients) Program, a province-wide cessation program that has provided treatment to close to a quarter million Ontario smokers.

| OTTAWAMODEL | #OMSC2020FOLLOW US

1. TOBACCO RETAIL AVAILABILITY AND TOBACCO CESSATION IN LUNG AND HEAD AND NECK CANCER SURVIVORS | Lawson Eng, Jie Su, Steven Habbous, Katrina Hueniken, Todd A Norwood, M Catherine Brown, Deborah P. Saunders, John R. De Almeida, Andrew Hope, Andrea Bezjak, Adrian G. Sacher, Penelope A. Bradbury, Anna Spreafico, Aaron R Hansen, Frances A. Shepherd, Natasha B. Leighl, Andrew F. Pierre, Peter Selby, David P. Goldstein, Wei Xu, Meredith E. Giuliani, William K. Evans, Geoffrey Liu, Michael Chaiton

2. SEASONALITY OF ENROLMENTS, SERVICE USE, TREATMENT ENGAGEMENT, AND OUTCOMES IN A LARGE SMOKING-CESSATION PROGRAM IN ONTARIO, CANADA | Scott Veldhuizen, Laurie Zawertailo, Anna Ivanova, Sarwar Hussain, Peter Selby

3. IMPLEMENTING MEASURES FOR PATIENT-REPORTED OUTCOMES TO VERIFY THE EFFECTIVENESS OF SMOKING CESSATION (IMPROVE-SC) AMONG CANCER PATIENTS IN ONTARIO | Erin Cameron, Sargam Rana, Mohammad Haque, Naomi Schwartz, Sahara Khan, Vicki Lee, Rebecca Truscott, William K. Evans

4. IMPROVING ACCESS TO TREATMENT FOR SMOKERS WITH DEPRESSION: A CLUSTER RANDOMIZED TRIAL COMPARING THE EFFECTIVENESS OF TWO IMPLEMENTATION APPROACHES | Nadia Minian, Sheleza Ahad, Anna Ivanova, Laurie Zawertailo, Dolly Baliunas, Arun Ravindran, Claire de Oliveira, Carol Mulder, Aliya Noormohamed, and Peter Selby

5. TRYING TO CURE TOBACCO ADDICTION IN MANCHESTER, ENGLAND AND BEYOND | Cheryl Pearse, Matthew Evison, Freya Howle, Helen Huddart, Monique Baugh, Eileen Ashton, Michael Rutherford, Emily Manley, Alyshia Mawson, Katy Melia, Thirzah White, Carol Kearney

6. A TWO YEAR AUDIT OF THE CLINICAL AND DEMOGRAPHIC PROFILE OF PATIENTS ATTENDING A TOBACCO CESSATION CLINIC IN LAGOS, NIGERIA | Dr Oyapero Afolabi, Dr Erinoso Oluwafemi

7. THE IMPACT OF PSYCHIATRIC DISORDER DIAGNOSIS ON MOTIVATION TO QUIT AND SMOKING CESSATION STAGE OF CHANGE AMONG PATIENTS AT A HOSPITAL-BASED OUTPATIENT SMOKING CESSATION CLINIC | Jake Johnston, Joanna Xia, Kristina Yau, Jay Ching-Chieh Wang, Chizimuzo T.C. Okoli, Milan Khara

8. TOBACCO CESSATION IN OUTPATIENT ONCOLOGY CLINICS: ONE CANCER CENTRE’S EXPERIENCE USING THE 3AS MODEL AND THE OPT-OUT APPROACH TO TREATMENT OF TOBACCO DEPENDENCE | Sarah Blyth, Catherine Vanderwater, Julia Hartwick

9. EVALUATION OF A FREE NICOTINE REPLACEMENT THERAPY IN THE VITALITÉ HEALTH NETWORK'S SMOKING CESSATION CLINICS: A PRIMARY ANALYSIS | Guignard, K., Mallet, M.

10. THE OTTAWA MODEL FOR SMOKING CESSATION IN THE TORONTO WESTERN FAMILY HEALTH TEAM: A TAILORED APPROACH | Soumia Meiyappan, Teri Arany, Lillian Ferreira, Patricia Rodriguez, Jadie Lo, Benjamin Kaasa, Allison Mann, Sandra Palmer, Leah McDonell, Eugena Bryan, Yvonne Kwok, Rita Kang, Caroline Lawrance

11. SMOKING CESSATION AND HEALTH EQUITY: A UNIQUE APPROACH | Melissa Goheen, Rosemary Lamont, Norma Prosser, Jennifer Tiberio, Deborah Wood

12. ATTITUDES TOWARDS, INTENTION, AND ATTEMPTS TO QUIT SMOKING AMONG DIFFERENT SOCIODEMOGRAPHIC GROUPS WITHIN A LUNG CANCER SCREENING PROGRAM | Shubhangi Shah, Reenika Aggarwal, Andrew Lam, Eric Stewart, Geoffrey Liu

13. TRAITEMENT DU TABAGISME EN CANCÉROLOGIE | Nancy Lyons

14. SMOKING CESSATION FOR ONCOLOGY PATIENTS- AN OUTCOME EVALUATION | Elysia Desai, Scott Antle, Alissa Setliff, Desmond Martin

11

POSTER PRESENTATIONS

14

RAPID FIRE ORAL PRESENTATIONS

10

1. IMPROVING PATIENT CARE IN A TOBACCO DEPENDENCY PROGRAMME (IPCTD) -A QUALITY IMPROVEMENT PILOT FOR SMOKING CESSATION SUPPORT TO FAMILY MEMBERS WISHING TO QUIT SMOKING TO IMPROVE THE QUIT ENVIRONMENT OF THE SMOKING PREGNANT WOMAN | Heidi Croucher

2. TOBACCO RETAIL AVAILABILITY AND TOBACCO CESSATION IN LUNG AND HEAD AND NECK CANCER SURVIVORS | Lawson Eng

3. SEASONALITY OF ENROLMENTS, SERVICE USE, TREATMENT ENGAGEMENT, AND OUTCOMES IN A LARGE SMOKING-CESSATION PROGRAM IN ONTARIO, CANADA | Laurie Zawertailo

4. IMPROVING ACCESS TO TREATMENT FOR SMOKERS WITH DEPRESSION: A CLUSTER RANDOMIZED TRIAL COMPARING THE EFFECTIVENESS OF TWO IMPLEMENTATION APPROACHES | Laurie Zawertailo

5. IMPLEMENTING MEASURES FOR PATIENT-REPORTED OUTCOMES TO VERIFY THE EFFECTIVENESS OF SMOKING CESSATION (IMPROVE-SC) AMONG CANCER PATIENTS IN ONTARIO | Erin Cameron

6. TRYING TO CURE TOBACCO ADDICTION IN MANCHESTER, ENGLAND AND BEYOND | Cheryl Pearse

15

DISCLOSURE OF CONFLICTS OF INTEREST

The Office of Continuing Professional Development supports the CMA Policy Summary on Physicians and the Pharmaceutical Industry. Among other standards, it is now accepted practice to acknowledge potential conflicts of interest in CPD activities. The Office requires that all speakers disclose pertinent relationships they have with commercial organizations. A conflict of interest may exist if a speaker is affiliated with, or has a financial interest in commercial organizations that may have a direct or indirect interest in the subject matter of his/her presentation. A “financial interest” may include but is not limited to, being a shareholder in the organization, or having research or honoraria paid by the organization. An “affiliation” may be holding a position on an advisory committee or some other role of benefit to an organization.

The intent of disclosure is not to prevent a speaker with potential conflicts of interest from making a presentation but simply to make these known to the audience. With full disclosure of the pertinent relationships, participants may make their own conclusions about potential bias in presentations.

YONI FREEDHOFF • Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: Queens Dept. of Cardiology, New Brunswick Heart Centre, Obesity Canada, Ottawa Heart Institute, NovoNordisk

• Hold investments in a pharmaceutical organization, medical device company, or communications firm, or not-for-profit organization: Bariatric Medical Institute

STANTON GLANTZ • Member of an advisory board or speakers’ bureau: California Scientific Review Panel on Toxic Air Contaminants, Georgia State University Tobacco Center for Regulatory Science, American Heart Association A-TRAC Tobacco Center of Regulatory Science

• Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: NIH, Truth Initiative

DAVID HAMMOND • Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: CIHR, NIH

CAROLINE LAWRANCE • Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: University of Ottawa

HAYDEN MCROBBIE • Member of an advisory board or speakers’ bureau: Pfizer• Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: Pfizer

KERRI-ANNE MULLEN • Currently participating, or have participated, in a clinical trial within the past two years: CIHR

NARDINE NAKHLA • Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: Johnson & Johnson, Consumer Health Products Canada

LESLIE PHILLIPS • Received payment from an organization (including gifts or other consideration, or in-kind compensation): Johnson & Johnson

ANDREW PIPE • Member of an advisory board or speakers’ bureau: CIHR, Heart and Stroke Foundation• Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: Pfizer

BOB REID • Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: Pfizer

RACHEL TYNDALE • Member or an advisory board or speakers’ bureau: Quitta, Health Canada SAB on Vaping • Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: Pfizer

LAURIE ZAWERTAILO • Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: Pfizer

THE FOLLOWING SPEAKERS DECLARED THAT THEY HAD NO FINANCIAL INTERESTS, ARRANGEMENTS AND/OR AFFILIATIONS WITH ORGANIZATIONS SPONSORING THIS PROGRAM:

Michael Amato Priscilla Bélanger Rosa Dragonetti

William Evans

16

Jo-Anne GagnierJoanne Haddad

Rebecca JessemanSarah Mackler Ruth Malone

Donna PetteyJessica ReidLori Scholtz Kate Walker

ACKNOWLEDGMENTS

The University of Ottawa Heart Institute would like to thank the following organizations for educational grants in support of this event:

The University of Ottawa Heart Institute gratefully acknowledges the support of the Ministry of Health and Long-Term Care’s Smoke-Free Ontario Strategy.

Special thanks to the following individuals who have contributed their time to this event:

Priscilla Belanger Jo-Anne Gagnier

Pamela Heise Laura Hobler

Kelsey Jessup Cindy Knight-Vigneron

Caroline Lawrance Judith LachanceSadie Litchfied

Leigh MorrisRebecca NadlerManu Sandhu

Lori ScholtzDonna Taylor

Tasuku Terada Kate Walker

Kimberley Way Evyanne Wooding

17

SAVE THETHE DATE

13THTH ANNUALOTTAWA CONFERENCE

STATE OF THE ART CLINICAL APPROACHES TO SMOKING CESSATION

JANUARY 22-23, 2021